Business Description
Oramed Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US68403P2039
Compare
Compare
Traded in other countries / regions
ORMP.USAOJU1.GermanyORMP.Switzerland IPO Date
2007-05-01Description
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 207.46 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.37 | |||||
| Beneish M-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -23.6 | |||||
| 3-Year EBITDA Growth Rate | -4.8 | |||||
| 3-Year EPS without NRI Growth Rate | -4.7 | |||||
| 3-Year FCF Growth Rate | 0.6 | |||||
| 3-Year Book Growth Rate | 50.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.81 | |||||
| 9-Day RSI | 33.57 | |||||
| 14-Day RSI | 35.15 | |||||
| 6-1 Month Momentum % | 57.8 | |||||
| 12-1 Month Momentum % | -46.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 141.49 | |||||
| Quick Ratio | 141.49 | |||||
| Cash Ratio | 140.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.5 | |||||
| Shareholder Yield % | -0.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -996.23 | |||||
| Net Margin % | -747.02 | |||||
| ROE % | -13.25 | |||||
| ROA % | -12.55 | |||||
| ROIC % | -250.02 | |||||
| ROC (Joel Greenblatt) % | -1405.95 | |||||
| ROCE % | -15.39 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 37.78 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.68 | |||||
| EV-to-EBIT | 1.83 | |||||
| EV-to-EBITDA | 1.84 | |||||
| EV-to-Revenue | -16.26 | |||||
| EV-to-Forward-Revenue | 96.7 | |||||
| EV-to-FCF | 2.32 | |||||
| Price-to-Net-Current-Asset-Value | 0.71 | |||||
| Price-to-Net-Cash | 0.71 | |||||
| Earnings Yield (Greenblatt) % | 54.64 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ORMP
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oramed Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.703 | ||
| EPS (TTM) ($) | -0.51 | ||
| Beta | 1.81 | ||
| Volatility % | 132.16 | ||
| 14-Day RSI | 35.15 | ||
| 14-Day ATR ($) | 0.149481 | ||
| 20-Day SMA ($) | 2.846 | ||
| 12-1 Month Momentum % | -46.91 | ||
| 52-Week Range ($) | 1.81 - 13.73 | ||
| Shares Outstanding (Mil) | 40.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oramed Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oramed Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oramed Pharmaceuticals Inc Frequently Asked Questions
What is Oramed Pharmaceuticals Inc(ORMP)'s stock price today?
The current price of ORMP is $2.57. The 52 week high of ORMP is $13.73 and 52 week low is $1.81.
When is next earnings date of Oramed Pharmaceuticals Inc(ORMP)?
The next earnings date of Oramed Pharmaceuticals Inc(ORMP) is 2023-11-10 Est..
Does Oramed Pharmaceuticals Inc(ORMP) pay dividends? If so, how much?
Oramed Pharmaceuticals Inc(ORMP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers